NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative, non-invasive drug testing technologies. The challenges faced across these critical sectors are: ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...

Qabas is a leading technology provider in Saudi Arabia with a strong reputation for providing high-quality products and services across various sectors. With a deep understanding of the local market and a commitment to excellence, Qabas is well-positioned to drive the adoption of INBS' innovative drug screening solution in the country. NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapi ...

Core Insights - Intelligent Bio Solutions Inc. (NASDAQ: INBS) has successfully completed biocompatibility testing for its Intelligent Fingerprinting Drug Screening System, a crucial step for FDA 510(k) regulatory clearance [7][12] - The company plans to submit the 510(k) package in Q4 2024, aiming to launch the technology in the U.S. market by 2025 [3][4] Company Overview - Intelligent Bio Solutions Inc. specializes in innovative, rapid, non-invasive testing solutions, focusing on drug screening through fingerprint sweat analysis [4] - The Intelligent Fingerprinting Drug Screening System is designed to be hygienic and cost-effective, screening for drugs commonly used in workplace settings, including opiates, cocaine, methamphetamine, and cannabis [4] - The system allows for sample collection in seconds and provides results in under ten minutes, making it a valuable tool for employers in safety-critical industries [4] Regulatory Progress - The biocompatibility study adhered to ISO 10993 standards, confirming that all materials in the system are safe for medical device use [2] - The testing protocol included cytotoxicity, sensitization, and irritation tests, which were approved by the FDA for future premarket 510(k) submission [8][12]

Core Insights - Intelligent Bio Solutions Inc. (INBS) has successfully completed a biocompatibility study for its Intelligent Fingerprinting Drug Screening System, a crucial step towards FDA 510(k) regulatory clearance [2][6][7] - The company aims to submit the 510(k) package in Q4 2024, with plans to bring the technology to the U.S. market in 2025 [3][6] Company Overview - INBS is a medical technology company focused on innovative, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [1][6] - The system utilizes fingerprint sweat analysis to screen for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, providing results in under ten minutes [1][6] Technology and Applications - The Intelligent Fingerprinting Drug Screening System consists of a drug screening cartridge, a DSR-Plus reader, and a collection kit for laboratory analysis [3] - The technology is designed to be hygienic and cost-effective, making it suitable for safety-critical industries such as construction, manufacturing, transport, and drug treatment organizations [1][6] Regulatory Progress - The biocompatibility study adhered to ISO 10993 standards, confirming the safety of materials used in the drug screening system [2][6] - The FDA has approved the proposed testing approach for future premarket 510(k) submission, indicating a positive regulatory pathway for the company [7]

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its p ...

Dosing and sampling of the second cohort for the study concluded on Thursday, June 27, 2024, marking the completion of this phase and the end of the in-clinic portion of the study. The PK study aims to demonstrate that the Company's fingerprint sweat collection method provides results comparable to those from other specimen matrices, such as blood, saliva, and urine. INBS' first-of-its-kind fingerprint drug screening technology uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for ...

Doug Heath, Vice president of Global Sales at INBS, commented, "Our reach continues to extend into new sectors, indicating a demand for drug testing beyond just safety-critical industries. We're seeing more businesses taking proactive measures to ensure workplace safety and protect their reputation as responsible employers. We are very pleased to welcome these prominent retail partners into our growing network." For more information, visit: http://www.ibs.inc/ The recently secured accounts employ over 55,00 ...

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS' Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest and most recognized in the country. The recently secured accounts employ over 55,000 ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has successfully signed two new major customer accounts within the UK warehouse and logistics sector within the past three months. These accounts employ more than 15,000 individuals at more than 70 locations and will adopt INBS' innovative Intelligent Fingerprinting Drug Screenin ...